Ann: PAT-DX1 clinical development update, page-59

Well no Duke, you're wrong. If you carefully read the announcement and watched the webinar you would have seen that DX1 actually passed the spec tests. Some of the parameters only just passed, and the board has had previous experience knowing that it degrades over time. It decided that it would not be safe to use it in a clinical trial.

Big Pharma would probably be able to test DX1 in house with a large team, and also work out a solution to slow the degradation.

DX3 is a much more stable IGG to work with according to JC. They have used similar IGGs in the past so have knowledge about how to proceed.

Perhaps one of the smartest moves JC did was secure the patents.

In a startup biotec there is a high level of risk. The last week has been very disappointing to say the least. I'm not writing the company off just yet. If DX3 is proven to work in a ph1 then $8m will be a long forgotten joke.